Page last updated: 2024-10-30

ketotifen and Cancer of Prostate

ketotifen has been researched along with Cancer of Prostate in 1 studies

Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.
ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.

Research Excerpts

ExcerptRelevanceReference
"Neuroendocrine prostate cancer (NEPC), a highly aggressive subtype of prostate cancer displaying resistance to hormone therapy, presents a poor prognosis and limited therapeutic options."1.91Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway. ( Chen, L; Ji, Y; Li, A; Liu, B; Shen, K; Su, R; Wang, Q; Xue, W; Zhang, W; Zhu, Y, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Ji, Y1
Liu, B1
Chen, L1
Li, A1
Shen, K1
Su, R1
Zhang, W1
Zhu, Y1
Wang, Q1
Xue, W1

Other Studies

1 other study available for ketotifen and Cancer of Prostate

ArticleYear
Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway.
    Cellular oncology (Dordrecht), 2023, Volume: 46, Issue:5

    Topics: Animals; Cell Line, Tumor; Drug Repositioning; Humans; Interleukin-6; Ketotifen; Male; Mice; Prostat

2023